PR
JAZZ icon

PSP Research’s Jazz Pharmaceuticals JAZZ Stock Holding History

PSP Research’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
+971
New +$213K 0.12% 61
2026
Q1 		– Sell
-3,258
Closed -$554K – 91
2025
Q4 		$554K Buy
+3,258
New +$499K 0.48% 6

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

PSP Research's JAZZ Position: Q2 2026 in Review

PSP Research opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 971 shares worth $234K. The stake represents 0.12% of the portfolio and ranks #61 among its holdings. This is a return to the name: PSP Research previously reported a position in JAZZ as recently as Q4 2025.

PSP Research first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $554K in Q4 2025. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • PSP Research held 971 shares of Jazz Pharmaceuticals worth $234K as of Q2 2026.
  • Jazz Pharmaceuticals was a new PSP Research position in Q2 2026.
  • Jazz Pharmaceuticals made up 0.12% of PSP Research's portfolio in Q2 2026, its #61 holding.
  • PSP Research first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • PSP Research's Jazz Pharmaceuticals position peaked at $554K in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.